Carlos J Rodriguez, MD, discusses research presented at AHA 2021, which highlighted racial and ethnic disparities in anthracycline cardiotoxicity — a topic with limited prior data.
Researchers examined the 4-year outcomes of the PRAGUE-17 trial, which compared the effectiveness of LAA closure against NOACs for preventing cardioembolic events in AF.
Researchers conducted an evaluation to validate whether the Sieira risk score model was effective for predicting risk of sudden cardiac death in Brugada syndrome.
Researchers set out to determine if using 3D-upsampled data from 2D-LGE-CMR sequences would be superior to conventional 2D assessment for identifying transmural scarring in patients with VT.
![Decisions regarding thromboprophylaxis requires weighing the risk of stroke against the risk of bleeding in each patient.[3,4] Numerous risk assessment tools are available, including CHADS2, CHA2DS2-VASc, and HAS-BLED. American and European guidelines recommend the use of CHA2DS2-VASc, which considers sex, age, and history of congestive HF, hypertension, stroke/transient ischemic attack/thromboembolism, vascular disease, and diabetes mellitus.[3,4] Compared with other stroke risk assessment measures, this tool performed best in identifying patients at low risk of stroke who did not require anticoagulation therapy.[12] Oral anticoagulation is recommended in any patient with a score ≥2 on the CHA2DS2-VASc. In these patients, warfarin or the novel anticoagulants dabigatran, rivaroxaban, apixaban, or edoxaban can be considered, except in the setting of moderate to severe chronic kidney disease, where reduced doses of direct thrombin or factor Xa inhibitors are preferable.[4]](https://www.thecardiologyadvisor.com/wp-content/uploads/sites/17/2019/01/slideshowsizeatrialfibrillati_1061315.jpg)
